JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green light to treat severe backflow through the aortic valve. | JenaValve has ...
Transit Officer Paul DeGeorge thought his son was lying on him. Then he realized something much scarier was happening.
Medical Device Network on MSN
JenaValve strikes US market first with approval in TAVR-AR indication
The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...
A patient in the United States has become the first in the country to receive Corcym's next-generation Perceval Plus(R) LANCELOT sutureless aortic valve, marking an important milestone in the ...
The Lancelot technology delivers enhanced hemodynamics through the integration of precision laser cutting and after ...
MedPage Today on MSN
First TAVR System Approved for Severe Aortic Regurgitation
Limited launch expected for JenaValve's Trilogy System ...
The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...
JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...
JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.
For all the innovation, engineering, and miniaturization that has helped to refine surgical and transcatheter aortic valve replacement over the last few decades, they still fall short of ideal. That ...
The Ross procedure, which can be used to treat young people with severe aortic valve disease, has seen wide swings in popularity over the years, but now, with consistent data on long-term survival and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results